Last reviewed · How we verify
Tetracycline, Metronidazole, Bismuth subcitrate
Tetracycline, Metronidazole, Bismuth subcitrate is a Antibiotic combination therapy Small molecule drug developed by Mackay Memorial Hospital. It is currently FDA-approved for Helicobacter pylori infection and associated peptic ulcer disease. Also known as: Bismuth Trioxide.
This triple-drug combination eradicates Helicobacter pylori by combining tetracycline's protein synthesis inhibition, metronidazole's DNA damage, and bismuth's bacterial cell wall disruption.
This triple-drug combination eradicates Helicobacter pylori by combining tetracycline's protein synthesis inhibition, metronidazole's DNA damage, and bismuth's bacterial cell wall disruption. Used for Helicobacter pylori infection and associated peptic ulcer disease.
At a glance
| Generic name | Tetracycline, Metronidazole, Bismuth subcitrate |
|---|---|
| Also known as | Bismuth Trioxide |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Antibiotic combination therapy |
| Target | Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Metronidazole generates reactive oxygen species that damage bacterial DNA. Bismuth subcitrate disrupts the bacterial cell wall and enhances the bactericidal activity of the other agents. Together, they form a potent triple therapy regimen for H. pylori eradication.
Approved indications
- Helicobacter pylori infection and associated peptic ulcer disease
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Metallic taste (metronidazole)
- Photosensitivity (tetracycline)
- Black stool discoloration (bismuth)
Key clinical trials
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma (PHASE2)
- Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains (PHASE4)
- 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetracycline, Metronidazole, Bismuth subcitrate CI brief — competitive landscape report
- Tetracycline, Metronidazole, Bismuth subcitrate updates RSS · CI watch RSS
- Mackay Memorial Hospital portfolio CI
Frequently asked questions about Tetracycline, Metronidazole, Bismuth subcitrate
What is Tetracycline, Metronidazole, Bismuth subcitrate?
How does Tetracycline, Metronidazole, Bismuth subcitrate work?
What is Tetracycline, Metronidazole, Bismuth subcitrate used for?
Who makes Tetracycline, Metronidazole, Bismuth subcitrate?
Is Tetracycline, Metronidazole, Bismuth subcitrate also known as anything else?
What drug class is Tetracycline, Metronidazole, Bismuth subcitrate in?
What development phase is Tetracycline, Metronidazole, Bismuth subcitrate in?
What are the side effects of Tetracycline, Metronidazole, Bismuth subcitrate?
What does Tetracycline, Metronidazole, Bismuth subcitrate target?
Related
- Drug class: All Antibiotic combination therapy drugs
- Target: All drugs targeting Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth)
- Manufacturer: Mackay Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori infection and associated peptic ulcer disease
- Also known as: Bismuth Trioxide
- Compare: Tetracycline, Metronidazole, Bismuth subcitrate vs similar drugs
- Pricing: Tetracycline, Metronidazole, Bismuth subcitrate cost, discount & access